查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
乳腺癌藥物市場-全球行業規模、份額、趨勢、機會和預測，2017-2027 年按療法細分（按化療藥物、激素療法、靶向療法、最終用戶、地區）
市場調查報告書
商品編碼
1228257

乳腺癌藥物市場-全球行業規模、份額、趨勢、機會和預測，2017-2027 年按療法細分（按化療藥物、激素療法、靶向療法、最終用戶、地區）

Breast Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Therapy, By (Chemotherapy Drugs, By Hormone Therapy, By Targeted Therapy, By End User, and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在 2023 年至 2027 年的預測期內，全球乳腺癌治療市場預計將以驚人的複合年增長率增長。

易患癌症等慢性病的老年人口不斷增加，這推動了全球乳腺癌藥物市場的增長。

乳腺癌病例的增加促進了市場增長

全球乳腺癌患病率的上升以及許多患者對有效治療的需求不斷增加，預計將推動乳腺癌治療市場的增長。 乳腺癌被認為是世界上流行的癌症之一，診斷解決方案的改進有望推動市場增長。 對預防醫學和早期治療的需求不斷增長，由於其諸多好處，正促使個人進行診斷程序，進一步推動全球乳腺癌藥物市場的增長。

政府宣傳計劃的啟動推動市場增長

政府機構發起的乳腺癌篩查計劃和公共機構推出的支持計劃有望刺激全球乳腺癌藥物市場的增長。 根據世界衛生組織的一份報告，及早發現乳腺癌有助於最大限度地降低乳腺癌死亡率並加快乳腺癌患者的生存期。 世界各地的許多政府機構都在鼓勵乳腺癌篩查，尤其是在 50 歲以上的女性中。 此類篩查舉措和意識計劃促進了有效治療乳腺癌的藥物的可用性，並有望在預測期內推動全球乳腺癌藥物市場的增長。

不斷增長的靶向治療需求推動市場增長

對於全世界的腫瘤學家來說，治療乳腺癌是一項艱鉅的任務。 治療的可用性和選擇因患者而異。 靶向治療優於所有其他治療，因為它可以精確靶向乳腺癌細胞而不傷害周圍的健康細胞。 靶向治療幫助醫療專業人員克服傳統治療的局限性。 靶向治療還有助於腫瘤學家專注於預防性而非反應性治療。 該療法將提高診斷為晚期乳腺癌患者的治療效率，進一步促進全球乳腺癌藥物市場的增長。

可自定義

TechSci Research 根據預先確定的市場數據為您公司的獨特需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場公司（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章產品療法概述

第二章研究方法論

第 3 章 COVID-19 對全球乳腺癌藥物市場的影響

第四章客戶反饋

第 5 章執行摘要

第 6 章乳腺癌藥物的全球市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按治療方法（化學療法、激素療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、專科診所、門診手術中心、其他）
    • 按公司分類（2021 年）
    • 按地區
  • 產品市場地圖

第七章北美乳腺癌藥物市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按治療方法（化學療法、激素療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、專科診所、門診手術中心、其他）
    • 按國家
  • 北美分析
    • 美國
    • 墨西哥
    • 加拿大

第八章歐洲乳腺癌藥物市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按治療方法（化學療法、激素療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、專科診所、門診手術中心、其他）
    • 按國家
  • 歐洲國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第 9 章亞太地區乳腺癌藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按治療方法（化學療法、激素療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、專科診所、門診手術中心、其他）
    • 按國家
  • 亞太國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第 10 章南美乳腺癌藥物市場展望

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按治療方法（化學療法、激素療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、專科診所、門診手術中心、其他）
    • 按國家
  • 南美分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲的乳腺癌藥物市場前景

  • 市場規模和預測
    • 按金額
  • 市場份額和預測
    • 按治療方法（化學療法、激素療法、免疫療法、靶向療法等）
    • 最終用戶（醫院、專科診所、門診手術中心、其他）
    • 按國家
  • MEA：國家分析
    • 南非的乳腺癌藥物
    • 沙特阿拉伯的乳腺癌藥物
    • 阿聯酋的乳腺癌藥物

第 12 章市場動態

  • 司機
  • 任務

第13章新興國家市場趨勢與發展

第14章競爭格局

  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly & Company
  • Merck Co. & Inc.
  • GlaxoSmithKline, Plc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Halozyme Inc.
  • Eisai Co., Ltd.
  • Fresenius Kabi AG

第15章 戰略的提言

簡介目錄
Product Code: 10617

The global breast cancer therapeutics market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. The growing geriatric population who are more susceptible to several chronic illnesses such as cancer is propelling the growth of the global breast cancer therapeutics market.

The rising incidences and high prevalence rate of breast cancer across the world are expected to augment the global breast cancer therapeutics market. With this, extensive investment in research and development activities and technological advancements in cancer biology and pharmacology promote breast cancer therapeutics. Continuous upgrades help increase understanding of breast cancer at the molecular level, and the introduction of novel solutions has assisted in lowering the breast cancer mortality rate over the past few years. Newly developed therapeutics efficiently slow down the growth and proliferation of cancerous cells, which is projected to boost the global breast cancer therapeutics market in the upcoming years.

Rise in Cases of Breast Cancer Augments the Market Growth

The growing prevalence of breast cancer across the globe and the escalating demand for effective treatment for a large number of patients are expected to stimulate the growth of the breast cancer therapeutics market. Breast cancer is considered one of the prevalent forms of cancer across the world, and enhanced diagnostic solutions are expected to propel market growth. The escalating demand for preventive care and early treatment due to its numerous benefits led individuals to go for diagnostic procedures, further driving the global breast cancer therapeutics market growth.

Launch of Awareness Programs by Government Stimulates the Market Growth

The breast cancer screening initiatives by government bodies and supportive programs introduced by public organizations are anticipated to stimulate the growth of the global breast cancer therapeutics market. According to the WHO report, early detection of breast cancer assists in minimizing the breast cancer mortality rate and accelerates the survival rate among patients who have breast cancer. Numerous government bodies across the globe encourage people to undergo breast cancer screening, especially women aged 50 and over. The screening initiatives and awareness programs are projected to propel the utilization of drugs for the effective treatment of breast cancer, driving the global breast cancer therapeutics market growth over the forecast period.

Escalating Demand for Targeted Therapy Supports the Market Growth

Treatment for breast cancer across the globe is a challenging task for any medical oncologist. The availability of treatment and choice varies from patient to patient. Targeted therapy is preferred over any other therapy as it precisely targets the breast cancer cells without damaging the surrounding healthy cells. The targeted therapy aids medical professionals in overcoming numerous limitations posed by traditional treatments. Targeted therapy also helps oncologists focus more on preventive care than reactive care. This therapy enhances the treatment efficiency in patients diagnosed with advanced stages of breast cancer, which further contributes to the growth of the global breast cancer therapeutics market.

Market Segmentation

The global breast cancer therapeutics market is segmented into type, end users, and regional distribution. Based on the type, the market is divided into chemotherapy, hormone therapy, immunotherapies, targeted therapy, and others. The chemotherapy drugs are further divided into anthracyclines, taxanes, and antimetabolites, and hormone therapy is divided into selective estrogen receptor modulators, aromatase inhibitors, and others. Also, the targeted therapy is divided into monoclonal antibodies, a tyrosine kinase inhibitor, Herceptin, and others. Based on the end users, the market is divided into hospitals, specialty clinics, ambulatory surgical centers, and others. The market analysis also studies the regional segmentation, divided among the North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, Pfizer Inc., Eli Lilly & Company, Merck Co. & Inc., GlaxoSmithKline, Plc., AstraZeneca Plc., Bristol-Myers Squibb Company, Halozyme Inc., Eisai Co., Ltd., Fresenius Kabi AG are the leading market players contributing the growth of the global breast cancer therapeutics market.

Report Scope

In this report, global breast cancer therapeutics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Diagnostics Market, By Therapy:

  • Chemotherapy
    • Anthracyclines
    • Taxanes
    • Antimetabolites
    • Others
  • Hormone Therapy
    • Selective Estrogen Receptor Modulators
    • Aromatase Inhibitors
    • Others
  • Immunotherapies
  • Targeted Therapy
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitor
    • Herceptin
    • Others
  • Others

Breast Cancer Diagnostics Market, By End-User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Breast Cancer Diagnostics, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global breast cancer therapeutics market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Therapy Overview

2. Research Methodology

3. Impact of COVID-19 on Global Breast Cancer Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Global Breast Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 6.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 6.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 6.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 6.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.3. By Company (2021)
    • 6.2.4. By Region
  • 6.3. Product Market Map

7. North America Breast Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 7.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 7.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 7.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 7.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Breast Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy
        • 7.3.1.2.2. By End User
    • 7.3.2. Mexico Breast Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy
        • 7.3.2.2.2. By End User
    • 7.3.3. Canada Breast Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy
        • 7.3.3.2.2. By End User

8. Europe Breast Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 8.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 8.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 8.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 8.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Breast Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy
        • 8.3.1.2.2. By End User
    • 8.3.2. Germany Breast Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy
        • 8.3.2.2.2. By End User
    • 8.3.3. United Kingdom Breast Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy
        • 8.3.3.2.2. By End User
    • 8.3.4. Italy Breast Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy
        • 8.3.4.2.2. By End User
    • 8.3.5. Spain Breast Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy
        • 8.3.5.2.2. By End User

9. Asia-Pacific Breast Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 9.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 9.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 9.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 9.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Breast Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy
        • 9.3.1.2.2. By End User
    • 9.3.2. India Breast Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy
        • 9.3.2.2.2. By End User
    • 9.3.3. Japan Breast Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy
        • 9.3.3.2.2. By End User
    • 9.3.4. South Korea Breast Cancer Therapeutics Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Therapy
        • 9.3.4.2.2. By End User
    • 9.3.5. Australia Breast Cancer Therapeutics Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Therapy
        • 9.3.5.2.2. By End User

10. South America Breast Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 10.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 10.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 10.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 10.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Breast Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy
        • 10.3.1.2.2. By End User
    • 10.3.2. Argentina Breast Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy
        • 10.3.2.2.2. By End User
    • 10.3.3. Colombia Breast Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy
        • 10.3.3.2.2. By End User

11. Middle East and Africa Breast Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy (Chemotherapy, Hormone Therapy, Immunotherapy, Targeted Therapy, Others)
      • 11.2.1.1. Chemotherapy Drugs (Anthracyclines, Taxanes, Antimetabolites, Others)
      • 11.2.1.2. Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Others)
      • 11.2.1.3. Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, Others)
    • 11.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Breast Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Therapy
        • 11.3.1.2.2. By End User
    • 11.3.2. Saudi Arabia Breast Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Therapy
        • 11.3.2.2.2. By End User
    • 11.3.3. UAE Breast Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Therapy
        • 11.3.3.2.2. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Novartis AG
  • 14.2. Pfizer Inc.
  • 14.3. Eli Lilly & Company
  • 14.4. Merck Co. & Inc.
  • 14.5. GlaxoSmithKline, Plc.
  • 14.6. AstraZeneca Plc.
  • 14.7. Bristol-Myers Squibb Company
  • 14.8. Halozyme Inc.
  • 14.9. Eisai Co., Ltd.
  • 14.10. Fresenius Kabi AG

15. Strategic Recommendations